(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 16.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Ionis Pharmaceuticals's revenue in 2025 is $717,252,000.On average, 9 Wall Street analysts forecast IONS's revenue for 2025 to be $118,365,348,654, with the lowest IONS revenue forecast at $116,104,971,130, and the highest IONS revenue forecast at $125,162,715,454. On average, 10 Wall Street analysts forecast IONS's revenue for 2026 to be $137,605,296,336, with the lowest IONS revenue forecast at $123,825,779,022, and the highest IONS revenue forecast at $157,726,667,109.
In 2027, IONS is forecast to generate $178,794,716,203 in revenue, with the lowest revenue forecast at $64,300,275,996 and the highest revenue forecast at $216,615,533,739.